Postorgasmic Illness Syndrome: What do we know so far?

Abstract

Post-orgasmic illness syndrome (POIS) is rare condition that is characterized by transient flu-like symptoms and cognition disorders that occur shortly after ejaculation and last for 2-7 days. There are about 50 cases of POIS in the literature. The prevalence and incidence of POIS are still unknown due to a paucity of studies. The exact pathogenesis of POIS remains unknown; the most acceptable hypothesis is an autoimmune/allergic process. We made a literature search via PubMed for publications from 2002 to 2018 with the "post orgasmic illness syndrome" medical subject heading term to analyze current data regarding symptoms, burden, pathophysiology, and to discuss potential management options for POIS. POIS is diagnosed by five preliminary diagnostic criteria. It is categorized into two types: primary and secondary. There is the concomitance between POIS and PE. The autoimmune/allergy hypothesis is the most accepted hypothesis explaining POIS pathogenesis. A competing hypothesis involves a disorder of endogenous μ-opioid receptors. Patients with POIS have been symptomatically treated with antihistamines, selective serotonin reuptake inhibitors, and benzodiazepines. A trial of hyposensitization therapy with autologous semen was successful. A trial of nonsteroidal anti-inflammatory medication helped in a single case report but failed to successfully treat other patients with POIS.

Intermolecular Enantioselective Benzylic C(sp3)−H Amination by Cationic Copper Catalysis**

“…First, amide 3 l was deprotected with Schwartz reagent under mild conditions to give a chiral primary amine with no loss in enantiomeric purity (Scheme 4A). [16] Three chiral drugs-(R)-tecalcet (8), a calcimimetic compound for treating hyperparathyroidism; [17] dapoxetine (10), which is used to treat premature ejaculation; [18] and rivastigmine (12), an Alzheimer's drug [19] --were readily prepared via routes involving enantioselective amination as the key step (Scheme 4B). In addition, SARS-CoV PLpro inhibitor [20] 13 was synthesized in one step.…”

Intermolecular Enantioselective Benzylic C(sp3)−H Amination by Cationic Copper Catalysis**

“…First, amide 3 l was deprotected with Schwartz reagent under mild conditions to give a chiral primary amine with no loss in enantiomeric purity (Scheme 4A). [16] Three chiral drugs-(R)-tecalcet (8), a calcimimetic compound for treating hyperparathyroidism; [17] dapoxetine (10), which is used to treat premature ejaculation; [18] and rivastigmine (12), an Alzheimer's drug [19] --were readily prepared via routes involving enantioselective amination as the key step (Scheme 4B). In addition, SARS-CoV PLpro inhibitor [20] 13 was synthesized in one step.…”